New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
08:06 EDTNVIVInvivo Therapeutics receives notice of allowance from USPTO
InVivo Therapeutics Holdings Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 14/177,888, titled “Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries”. The application covers InVivo’s Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial, and its Neuro-Spinal Scaffold combined with stem cells, which is being developed for the treatment of chronic spinal cord injury. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children’s Hospital and the Massachusetts Institute of Technology. A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
News For NVIV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 3, 2016
08:05 EDTNVIVInVivo says UCSD Medical Center new site for INSPIRE study
InVivo Therapeutics announced that University of California, San Diego Medical Center has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. UC San Diego Medical Center, located in Hillcrest, has 390 beds and is one of only two Level I Trauma Centers in San Diego County. Joseph Ciacci, M.D., Clinical Professor of Surgery at the UC San Diego School of Medicine and Chief of Neurosurgery at the Veteran Affairs San Diego Healthcare System, has been named Principal Investigator at the site.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use